《藍籌業績》石藥(01093.HK)首三季純利44.95億人幣 按年升0.6%
石藥集團(01093.HK)公布截至今年9月底止首三季業績,營業額238.65億元人民幣(下同),按年升1.6%。純利44.95億元,按年升0.6%;每股盈利37.84分。期內,按非香港財務報告準則指標的股東應佔基本溢利為47.15億元,按年增長近2%。
按業務劃分之收入方面,成藥收入按年增長3.9%至193.38億元;原料產品收入跌8.2%至28.75億元;功能食品及其它收入跌5.6%至16.52億元。
此外,集團本期研發費用達36.78億元,按年增長25.9%,約佔成藥業務收入的19%。目前有約60個重點在研藥物已進入臨床或申報階段,其中7個已遞交上市申請,17處於註冊臨床或即將遞交上市申請的階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.